Granted Patent B2

US 12,544,382 · App. 17/616,571 · Granted Feb 10, 2026

Inventors: Yanping Zhao (Beijing, CN); Hongjun Wang (Beijing, CN); Bin Liu (Beijing, CN); Yuanyuan Jiang (Beijing, CN); Weiting Zhong (Beijing, CN); Huifen Xu (Beijing, CN); Honglei Zhang (Beijing, CN); Chuangchuang Huang (Beijing, CN); Nana Tian (Beijing, CN); Jing Zhao (Beijing, CN); Jing Li (Beijing, CN); Weina Liu (Beijing, CN); Liying Zhou (Beijing, CN); Yanan Liu (Beijing, CN)

Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.

A61K31/5377A61P35/00C07D413/14C07D471/04

Abstract

Claims (148)

1 . A compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof:

wherein,

X is CH or N; Y is CH or N; and wherein at least one of X and Y is N;

R 1 , R 2 , R 3 and R 4 are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl; or R 1 and R 2 , R 3 and R 4 are connected to form bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene; at least one of R 1 and R 2 is C 1-6 alkyl;

is

ring B is 5- to 10-membered heteroaryl;

R a1 and R a3 are independently selected from H, halogen, —CN, -L-NRR′, -L-OR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, -L-S(O) p R*, -L-S(═O)(═NR)R*, -L-C 3-7 cycloalkyl and -L-4- to 8-membered heterocyclyl, each of which is optionally substituted with R** group;

R a2 is selected from -L-C 3-7 cycloalkyl and -L-4- to 8-membered heterocyclyl, which is optionally substituted with R** group;

wherein L is independently selected from bond, —O—, —S—, —NR—, —C(O)—, C 1-6 alkylene, C 2-6 alkenylene and C 2-6 alkynylene; p=1 or 2;

R*is selected from C 1-6 alkyl, C 1-6 haloalkyl, -L′-NRR′, -L′-OR, -L′-C 3-7 cycloalkyl and -L′-4- to 8-membered heterocyclyl; wherein L′ is independently selected from bond, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, —O—C 1-6 alkylene and —NH—C 1-6 alkylene;

R b is independently selected from H, halogen, —CN, —OH, C 1-6 alkyl, C 1-6 alkoxy, -L-C 3-7 cycloalkyl, -L-3- to 8-membered heterocyclyl, —NRR′, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′ and —NRC(O)NRR′;

R** is independently selected from H, halogen, —CN, —C(═O)R, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, 4- to 8-membered heterocyclyl, —S(O) p —C 1-6 alkyl, —S(O) p —C 1-6 haloalkyl and —NRR′;

R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl, or R, R′ are taken together with the nitrogen atoms to which they are attached to form 4- to 8-membered heterocyclyl;

n=0, 1, 2, 3, 4 or 5.

2 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (II):

wherein, Y, ring A, ring B, R b and n are as defined in claim 1 ;

alternatively,

R a1 is selected from H, C 1-6 alkyl and C 1-6 haloalkyl; alternatively is H or methyl;

R a2 is as defined in claim 1 ; alternatively, R a2 is -L-4- to 8-membered heterocyclyl, which is optionally substituted with R** group; wherein L is selected from bond, C 1-6 alkylene, C 2-6 alkenylene and C 2-6 alkynylene, p=1 or 2; R** is selected from H, halogen, —OR, —C(O)R, C 1-6 alkyl, C 1-6 haloalkyl, 4- to 8-membered heterocyclyl, —S(O) p —C 1-6 alkyl, —S(O) p —C 1-6 haloalkyl and —NRR′, wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl;

R a3 is selected from H, C 1-6 alkyl and C 1-6 haloalkyl; alternatively is H or methyl;

ring B is selected from

R b is selected from H, halogen, C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl, halogen or methylamino;

n=0, 1, 2, 3 or 4; alternatively, n=0, 1 or 2.

3 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (III):

wherein, Y, ring A, R a and m are as defined in claim 2 ;

R a1 is selected from C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl;

R a2 is as defined in claim 2 ; alternatively, R a2 is -L-4- to 8-membered heterocyclyl, which is optionally substituted with R** group; wherein L is selected from bond, C 1-6 alkylene, C 2-6 alkenylene and C 2-6 alkynylene, p=1 or 2; R** is selected from H, halogen, —OR, —C(O)R, C 1-6 alkyl, C 1-6 haloalkyl, 4- to 8-membered heterocyclyl, —S(O) p —C 1-6 alkyl, —S(O) p —C 1-6 haloalkyl and —NRR′, wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl;

R a3 is selected from C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl.

4 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (IV):

wherein,

X is CH or N;

ring A is:

R a1 is selected from H, C 1-6 alkyl and C 1-6 haloalkyl; alternatively is H or methyl;

R a2 is -L-4- to 8-membered heterocyclyl, which is optionally substituted with R** group; wherein L is selected from bond, C 1-6 alkylene, C 2-6 alkenylene and C 2-6 alkynylene, p=1 or 2; R** is selected from H, halogen, —OR, —C(O)R, C 1-6 alkyl, C 1-6 haloalkyl, 4- to 8-membered heterocyclyl, —S(O) p —C 1-6 alkyl, —S(O) p —C 1-6 haloalkyl and —NRR′, wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl;

alternatively, R a2 is -L-4- to 8-membered heterocyclyl, wherein L is bond or C 1-6 alkylene; alternatively is azetidin-3-ylmethyl, oxetan-3-ylmethyl, pyran-4-yl, tetrahydropyrrolyl or piperidinyl;

R a3 is selected from H, C 1-6 alkyl and C 1-6 haloalkyl; alternatively is H, methyl, CF 3 ;

R b is selected from H, halogen, —CN, —OH, C 1-6 alkyl, C 1-6 alkoxy, -L-C 3-7 cycloalkyl, -L-3- to 8-membered heterocyclyl, —NRR′, —C(O)R; alternatively is H, halogen, methoxy or —CH 2 -azetidin-3-yl;

n=0, 1, 2 or 3.

5 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (IV):

wherein,

X is CH or N;

ring A is:

R a1 is selected from C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl;

R a2 is -L-4- to 8-membered heterocyclyl, which is optionally substituted with R** group, wherein L is selected from bond, C 1-6 alkylene, C 2-6 alkenylene and C 2-6 alkynylene; R** is selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, —S(O) p —C 1-6 alkyl and —S(O) p —C 1-6 haloalkyl, wherein p=1 or 2;

alternatively, R a2 is selected from -L-4- to 8-membered heterocyclyl, pyran-4-yl, tetrahydropyrrolyl or piperidinyl;

R a3 is selected from H, C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl, CF 3 ;

R b is selected from H, halogen, —CN, —OH, C 1-6 alkyl, C 1-6 alkoxy, -L-C 3-7 cycloalkyl, -L-3- to 8-membered heterocyclyl, —NRR′, —C(O)R; alternatively is H, halogen, methoxy or —CH 2 -azetidin-3-yl, and wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl, or R, R′ are taken together with the nitrogen atoms to which they are attached to form 4- to 8-membered heterocyclyl;

n=0, 1, 2 or 3.

6 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (V):

wherein,

X is CH or N;

R a1 is selected from C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl;

R a2 is L-4- to 8-membered heterocyclyl; alternatively is piperidinyl;

R a3 is selected from C 1-6 alkyl and C 1-6 haloalkyl; alternatively is methyl or trifluoromethyl;

ring B is selected from:

R b is selected from H, halogen, —CN, —OH, C 1-6 alkyl, C 1-6 alkoxy, -L-C 3-7 cycloalkyl, -L-3- to 8-membered heterocyclyl, —NRR′ and —NRC(O)R′, wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl;

L is selected from bond and C 1-6 alkylene;

n=0, 1, 2, 3, 4 or 5; alternatively, n=0, 1 or 2.

7 . A compound, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof, which has the structure of formula (VI):

wherein,

X is CH or N;

R a4 is -L-S(O) 2 R*, which is optionally substituted with R** group; wherein, L is selected from bond and C 1-6 alkylene, R* is selected from C 1-6 alkyl, C 1-6 haloalkyl, -L′-NRR′ and -L′-4- to 8-membered heterocyclyl; and wherein L′ is selected from bond and C 1-6 alkylene, R and R′ are independently selected from H, C 1-6 alkyl, or R, R′ are taken together with the nitrogen atoms to which they are attached to form 4- to 8-membered heterocyclyl; R** is selected from H, —CN, C(═O)R, C 1-6 alkyl, C 1-6 haloalkyl, —S(O) p —C 1-6 alkyl, —S(O) p —C 1-6 haloalkyl and —NRR′, wherein p=1 or 2;

alternatively, R a4 is —S(O) 2 R*, wherein, R* is selected from C 1-6 alkyl, -L′-NRR′ and 4- to 8-membered heterocyclyl, and wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl, or R, R′ are taken together with the nitrogen atoms to which they are attached to form 4- to 8-membered heterocyclyl; L′ is selected from bond and C 1-6 alkylene; alternatively is —SO 2 N(Me) 2 , —SO 2 Me, -SO 2 iPr or —SO 2 -piperidin-4-yl;

R a5 is selected from methyl, methoxy, isopropyl or trifluoromethyl;

ring B is selected from:

R b is selected from H, halogen, —CN, —OH, C 1-6 alkyl, C 1-6 alkoxy, -L-C 3-7 cycloalkyl, -L-3- to 8-membered heterocyclyl, —NRR′ and —NRC(O)R′, wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl;

n=0, 1, 2, 3, 4 or 5; alternatively, n=0, 1 or 2.

8 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (VII):

wherein,

ring C is C 3-7 cycloalkyl or 4- to 8-membered heterocyclyl, each of which is substituted with R a12 (alternatively 5- to 6-membered heterocyclyl substituted with R a12 , alternatively 5- to 6-membered heterocyclyl containing N atom(s) substituted with R a12 );

R a1 is C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy or C 1-6 haloalkoxy (alternatively methyl, trifluoromethyl or methoxy);

R a3 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively methyl or trifluoromethyl);

R a12 is H, C 1-6 alkyl or C 1-6 haloalkyl;

R 5 is H, halogen, C 1-6 alkyl or C 1-6 haloalkyl;

Z 1 is N or CR b1 ;

Z 2 is N or CR b2 ;

Z 3 is N or CR b3 ;

Z 4 is NR b4 or C(R b4 ) 2 ;

Z 5 is N or CR b5 ;

Z 6 is N or CR b6 ;

R b1 , R b2 , R b3 , R b4 , R b5 and R b6 are independently selected from H, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy and C 1-6 haloalkoxy (alternatively selected from H, halogen and methoxy);

alternatively,

R a1 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively methyl or trifluoromethyl);

R b2 is H or halogen (alternatively H or F);

R b3 is alternatively H;

alternatively,

at least one of R a1 and R a3 is C 1-6 haloalkyl.

9 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (VIII):

wherein,

ring C is

wherein the point of attachment with the rest of the molecule is at one of the positions shown by *;

R a1 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively is methyl or trifluoromethyl);

R a3 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively is methyl or trifluoromethyl);

R a12 is H or C 1-6 alkyl (alternatively is H or methyl);

R 5 is H or halogen (alternatively is H or F);

ring B is selected from

R b is H, methoxy or halogen (alternatively is H or halogen);

n is 0, 1, 2 or 3;

alternatively,

at least one of R a1 and R a3 is C 1-6 haloalkyl.

10 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (IX):

wherein,

ring C is C 3-7 cycloalkyl or 4- to 8-membered heterocyclyl, each of which is substituted with R a12 (alternatively 5- to 6-membered heterocyclyl substituted with R a12 , alternatively 5- to 6-membered heterocyclyl containing N atom(s) substituted with R a12 );

R a1 is C 1-6 alkyl or C 1-6 haloalkyl;

R a3 is C 1-6 alkyl or C 1-6 haloalkyl;

R a12 is H, C 1-6 alkyl or C 1-6 haloalkyl;

R 5 is H, halogen, C 1-6 alkyl or C 1-6 haloalkyl;

Z 7 is N or CR b7 ;

Z 8 is N or CR b8 ;

Z 9 is N or CR b9 ;

Z 10 is N or CR b10 ;

Z 11 is N or CR b11 ;

Z 12 is N or CR b12 ;

wherein,

R b7 is H, -L-OR, -L-C 1-6 alkyl, -L-C 3-7 cycloalkyl, —NRR′, —NRC(O)R′ or —NRC(O)NRR′;

R b8 , R b9 , R b10 , R b11 and R b12 are independently selected from H, halogen, —CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy and C 1-6 haloalkoxy (alternatively selected from H, halogen, —CN and methoxy);

L is independently selected from bond, —O—, —S—, —NR—, —C(O)—, C 1-6 alkylene, C 2-6 alkenylene and C 2-6 alkynylene;

R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl.

11 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 10 , wherein Z 7 is N or CR b7 ;

wherein,

R b7 is selected from —NRR′, —NRC(O)R′ or —NRC(O)NRR′;

wherein, R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl.

12 . The compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof according to claim 1 , which has the structure of formula (X):

wherein,

ring C is

wherein the point of attachment with the rest of the molecule is at one of the positions shown by *;

R a1 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively is methyl or trifluoromethyl);

R a3 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively is methyl or trifluoromethyl);

R a12 is H or C 1-6 alkyl (alternatively is H or methyl);

R 5 is H;

R b7 is selected from —NRR′, —SR, —NRC(O)R′ or —NRC(O)NRR′; wherein, R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl (alternatively, R b7 is selected from NH 2 , NHMe, NHEt, NHC(O)Me or NHC(O)Et);

R b is H or halogen (alternatively is H or F).

13 . A compound, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or mixture thereof, which has the structure of formula (XI):

wherein,

ring C is C 3-7 cycloalkyl or 4- to 8-membered heterocyclyl, each of which is substituted with R a12 (alternatively 5- to 6-membered heterocyclyl substituted with R a 12, alternatively 5- to 6-membered heterocyclyl containing N atom(s) substituted with R a12 );

R a1 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively is methyl or trifluoromethyl);

R a3 is C 1-6 alkyl or C 1-6 haloalkyl (alternatively is methyl or trifluoromethyl);

R a12 is H, C 1-6 alkyl or C 1-6 haloalkyl (alternatively is H or methyl);

R 5 is H, halogen, C 1-6 alkyl or C 1-6 haloalkyl (alternatively is H or F);

ring B is selected from:

R b is selected from H, halogen, —CN, -L-C 1-6 alkyl, C 1-6 alkoxy, -L-C 3-7 cycloalkyl, -L-3- to 8-membered heterocyclyl, —NRR′, —NRC(O)R′ and —NRC(O)NRR′, wherein R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl.

14 . A compound, which is selected from:

15 . A pharmaceutical composition, comprising:

the compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof according to claim 1 ; and

a pharmaceutically acceptable excipient;

alternatively, the pharmaceutical composition further comprises one or more other therapeutic agents.

16 . A method of treating and/or preventing diseases mediated by ATR kinase in a subject, which comprises administering to the subject the compound, or the pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof according to claim 1 .

17 . The method of claim 16 , wherein the said diseases mediated by ATR kinase includes: proliferative diseases (such as cancer), especially solid tumors (such as carcinoma and sarcoma), leukemia and lymphoma, especially breast cancer, colorectal cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer and bronchoalveolar cancer), prostate cancer and bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical cancer and vulvar cancer, and leukemia [including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML)], multiple myeloma and lymphoma.

Assignments (1)

Priority Claims (3)

Continuity (1)

References Cited (52)